Paris-Sana
The University Hospital of Grenoble in France announced the launch of a clinical trial aimed at slowing the progression of Parkinson's disease after the success of the first operation to implant a device that emits a near-infrared light in the brain.
The hospital said in a statement that this new therapeutic approach, which has been laboratory-confirmed for its effectiveness on animals, "can slow the loss of motor functions in patients with Parkinson's disease."
Parkinson's disease is a neurodegenerative condition that affects more than 6.5 million people worldwide, and no treatment is available for it.
Professor neurosurgeon Stefan Chapardis from the University of Grenoble said that deep brain stimulation by an electrode in the brain greatly relieves symptoms, but does not slow down the degenerative process, pointing out that the new technology is to produce near infrared light that targets the black matter in the brain. The site of the degeneration of the nerve cells responsible for the symptoms of the disease.
Shabardis added: By lighting dark matter, photons of light act on the affected cells as if they were to restore energy to them, explaining that this worked in mice, rats and monkeys, as it was proven that these infrared rays have significant effects on slowing the death of neurons related to the disease, but care must be taken.
On the twenty-fourth of last month, Shapardis successfully performed a surgery to implant the device for a woman with the disease who joined the clinical trial, and the research team seeks to involve 14 patients in the trials over a period of four years.
